Is NCT07156565 recruiting in Cleveland, OH?

Yes, NCT07156565 is currently recruiting participants at its Cleveland, OH location. This advanced soft tissue sarcoma clinical trial is actively enrolling qualified participants.

How do I join the advanced soft tissue sarcoma clinical trial in Cleveland?

To join this clinical trial in Cleveland, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Cleveland clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Advanced Soft Tissue Sarcoma Clinical Trial in Cleveland, OH

About This Advanced Soft Tissue Sarcoma Study in Cleveland

The goal of this clinical trial is to learn about the safety of drug \[Ac225\]RTX-2358 and the diagnostic imaging agent \[Cu64\]LNTH-1363S. Additionally Ratio Therapeutics will learn if \[Ac225\]RTX-2358 drug is effective in treating advanced sarcoma. The main questions the study aims to answer in Phase/Part 1 of the trial are: * Is \[Ac225\]RTX-2358 tolerable or does it cause toxicities (medical problems) in patients. * What is the most tolerable dose of \[Ac225\]RTX-2358 * Does the treatment show effectiveness on advanced sarcoma Participants will: * Take drug \[Ac225\]RTX-2358 once every 8 weeks (4 cycle target; 6 cycle maximum) over a period of 12 months * Visit the clinic three times for the first week of cycle one, then once a week for the remaining 7 weeks of cycle 1 for check-ups and tests. * For cycles 2-6: patient will visit the clinic once every 2 weeks for checkups and tests * Remain in long term follow-up for a period of four additional years

Sponsor: Ratio Therapeutics, Inc.

Who Can Participate

Inclusion Criteria

18 years of age or older.

History of relapse and refractory soft tissue sarcoma.

Histological confirmation of sarcoma at any point since diagnosis

At least 1 prior treatment regimen

Measurable disease as per RECIST (v1.1) for soft tissue sarcoma that is also positive on FAPi PET/CT or PET/MRI scan.

ECOG performance status of 0 or 1.

Adequate Organ reserve and renal function as evidenced by:

Neutrophil count ≥ 1200 µL without granulocyte colony stimulating factor

Platelet count ≥ 100,000 µL

Hemoglobin ≥ 8 g/dL

Total bilirubin level ≤ 1.5 × upper limit of normal (ULN).

Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN.

Calculated creatinine clearance ≥ 60 mL/min. 6. Coagulation parameters (prothrombin time, international normalized ratio and activated partial thromboplastin time) ≤ 1.5 × ULN 7. All patients (males and females of childbearing potential) must agree to practice 2 forms of highly effective contraceptive precautions to prevent pregnancy from the time consent is signed and throughout the trial. 8\. The patient or the patient's legal representative must be willing and able to provide written informed consent.

Exclusion Criteria

History of whole pelvic irradiation.

History of radioligand therapy.

Treatment within 14 days prior to first administration with:

Palliative surgery or external beam radiation.

Approved anticancer therapy including chemotherapy or immunotherapy.

Any investigational therapy.

Any major surgery (e.g., requiring general anesthesia).

Patients who are scheduled for external beam radiation therapy or radioligand therapy during the study period.

Congestive heart failure \> Class II New York Heart Association Functional Classification, current pericarditis, myocardial infarction within 6 months, or symptomatic coronary artery disease.

Patients with uncontrollable incontinence.

Unstable or clinically significant concurrent medical condition that would, in the opinion of the Investigator, jeopardize the safety of a patient and/or their compliance with the protocol.

Active infection requiring systemic antibacterial/antibiotic, antifungal, or antiviral therapy. Chronic antiviral therapy for stable viral disease can be included.

History of active fibrotic condition.

Any active malignancy other than sarcoma that requires treatment.

Stable brain metastasis is allowed but documented untreated metastases to brain or meninges are excluded.

Currently pregnant or lactating.

Known allergy to any of the study drugs or their excipients.

Inability or unwillingness to comply with any of the required imaging studies or study assessments.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Cleveland?

Yes, this clinical trial (NCT07156565) has an active research site in Cleveland, OH that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced Soft Tissue Sarcoma Treatment Options in Cleveland, OH

If you're searching for advanced soft tissue sarcoma treatment options in Cleveland, OH, this clinical trial (NCT07156565) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Cleveland research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced soft tissue sarcoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced soft tissue sarcoma clinical trials near you to find additional studies recruiting in your area.

Advanced Soft Tissue Sarcoma Clinical Trial in Cleveland, OH

Expert Care in Cleveland

IRB Approved

No-Cost Care

Apply for This Cleveland Location

Why Participate?

Simple Process